NorthLinks Bio, backed by RA Capital with $34M, is advancing HEX17 — an intranasal broad-spectrum viral prophylactic from Pneumagen — into a global Phase 2b protection study.
RA Capital Management is backing a startup that wants to design an intranasal prophylactic for respiratory viruses.
The company is called NorthLinks Bio and is …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Investors pour $115M into RQ Bio in search of a preventive flu drug
A New $500 Million Fund Is Trying to Eliminate the Common Cold
Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
Bionyra brings in $165M for next-generation immune drugs
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
'One injection protects up to six months': what is new HIV drug lenacapavir?
The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza…
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a…
RQ Bio has clinched $115 million in a Series A raise to advance a preclinical pipeline of virus-targeting antibodies.
Pfizer’s experimental 25-valent pneumococcal shot beats Prevnar 20; Relay Therapeutics charts $175M offering; Lilly to pay up to…
Innoviva launches Nortiva Bio to revive Lyndra's LYNX oral drug delivery platform, starting with a Gates-funded monthly…
The trend continues in which big-name venture investors band together to back new companies with an experimental medicine…
